VivoSeq
Other

Vaccination

0

Pipeline Programs↗

20

Active Trials↗

12

Companies Involved↗

Vaccination is an early-stage landscape with 0 programs across 12 companies. The most active players are GSK, Sanofi, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

217

clinical trials

Completed156 · 72%
Unknown status26 · 12%
Terminated10 · 5%
Active, not recruiting8 · 4%
Recruiting8 · 4%
Withdrawn3 · 1%
Other6 · 3%

Clinical Trials

Trial Activity

217 trials

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
Recruiting·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 1·NCT06484335·48 enrolled
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
Recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT03705585·240 enrolled
Characterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination
Recruiting·IIRCCS Sacro Cuore Don Calabria di Negrar·N/A·NCT06776692·402 enrolled
Evaluation of Patients' Knowledge of Their Vaccination Status and Their Relationship to Vaccination at Melun Hospital
Recruiting·GGroupe Hospitalier Sud Ile-de-France·N/A·NCT06616753·140 enrolled
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
Recruiting·RRockefeller University·Phase 4·NCT05272735·12 enrolled
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
Recruiting·UUniversity Hospital Tuebingen·Phase 1/2·NCT06094101·30 enrolled
Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
Recruiting·Sinovac Biotech Co., Ltd logoSinovac Biotech Co., Ltd·Phase 4·NCT07457060·480 enrolled
ARISe at UMass Chan: Remote Eye Tracking Study of Vaccine Messaging in Rural Populations
Recruiting·UUniversity of Massachusetts, Worcester·Preclinical·NCT07236034·700 enrolled
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
Active, not recruiting·VVirion Therapeutics·Phase 1·NCT06070051·56 enrolled
Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).
Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT07158190·30 enrolled
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
Active, not recruiting·UUniversity of Oxford·Phase 1·NCT06320535·36 enrolled
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Active, not recruiting·Sanofi logoSanofi·Phase 3·NCT06824181·580 enrolled
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
Active, not recruiting·—·Phase 1·NCT03560752·34 enrolled
ID93/GLA-SE Vaccination + BCG Challenge
Active, not recruiting·UUniversity of Oxford·N/A·NCT06670755·48 enrolled
Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers
Active, not recruiting·VVirometix·Phase 1·NCT06975319·60 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)